DNA Diagnostics Gets Digitised – Quantitative real-time PCR By Dr Mikael Kubista and Dr Anders Stahlberg Quantitative real-time PCR (qPCR) has during the last two decades emerged as the preferred technology for nucleic acid analysis in routine as well as in research. qPCR has… Read More
8 Years of Surveying Ion Channel Screening – Has anything changed? By Dr John Comley No review of ion channel screening over the past decade can avoid discussing the pivotal role played by automated electrophysiology. Arguably this technology, more than any other, has opened up the field… Read More
Dr Wilma Keighley Generally kinetics are only investigated late in a programme by which time many compounds, slightly less potent but with a much better kinetic profile, have already been discarded. This paper argues that having kinetic information at the early stages of drug discovery can… Read More
In Vivo Preclinical Imaging – An Essential Tool in Translational Research By Dr John Comley In vivo imaging of small animals (mainly mice) is increasingly being deployed across the drug development process, particularly in the oncology/cancer therapeutic area. One of the main applications is… Read More
Next Generation Flow Chemistry and Biology Platforms: The Impact on Small Molecule Drug Discovery By Dr J Mark Treherne, Dr David M Parry and Christopher N Selway Can the next generation of flow chemistry and biology platforms be fully integrated to transform the efficiency of small-molecule drug… Read More
In Vivo Cell Reprogramming: Current status and potential clinical applications By Dr Shili Wu, Jonathan Pang, Bobby Baravati, Jun Bao and Dr Yong Zhu In Vivo Cell Reprogramming, or IVR, is a new technology that can be used to develop cures for incurable diseases. Using a combination… Read More
3D Cell Culture Developments to Improve In Vitro Analyses By Prof Stefan Przyborski Improved in vitro models are required to aid the identification and assessment of candidate molecules for pharmaceutical development. Conventional cell culture models involve the growth of cells on two-dimensional (2D) substrates. Cells adapt to… Read More
Enabling the Promise of Stem Cells By Robert Shaw and Dr Jeff Till The remarkable potential of stem cells to generate several hundred differentiated cell types is driving their use for regenerative medicine and for supporting the traditional drug discovery and development process (Figure 1). Read More
The Post Genomic Era: What Does It All Mean? By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR was thought of by… Read More
By Michael Werner, Morrie Ruffin and Elizabeth West The regenerative medicine market offers phenomenal opportunities for growth in the next few decades. However, there are still major issues to be addressed to enable this nascent industry to truly flourish, especially with regard to investment and the… Read More
By Dr Cliff Murray Drug Discovery The pharmaceutical industry is still struggling to cure cancer despite pouring enormous resources into the search for new treatments. We take a look at the some of the current technologies for the discovery and delivery of molecular diagnostic, prognostic and… Read More
Epigenetics: An Emerging Target Class for Drug Screening By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone modifications encouraged HTStec to undertake market research in… Read More
The Benefits Of Drug Repositioning By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy… Read More
High Throughput Screening Systems: Impact of Reliability on Downtime and Drug Discovery By Dr John Comley This article reports the results of a survey on the reliability of automated HTS assay systems and the effect of reliability on output. Evidence supporting the view that high throughput screening (HTS)… Read More
Protein Biomarker Immunoassays: Opportunities and Challenges By Dr M. Walid Qoronfleh and Dr Klaus Lindpaintner With the biopharma industry under heavy pressure, transforming the scientific interchange between the laboratory and the clinic is exceedingly critical. Realising the costly toll of drug attrition in late-stage development, many companies… Read More
Induced Pluripotent Stem Cells: A model for transforming drug discovery By Dr Dwight Morrow and Dr Julie Holder Induced pluripotent stem (iPS) cells have the potential to transform drug discovery by providing physiologically relevant cells for toxic compound identification, target validation, compound screening, and tool discovery. The technology… Read More